HAVN Life Files Final Base Shelf Prospectus
VANCOUVER, BC, Oct. 7, 2021 VANCOUVER, BC , Oct. 7, 2021 /CNW/ – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) is pleased to announce that it has filed its final short form base shelf prospectus (the ” Final Shelf Prospectus “) with the securities commissions in each of the provinces and territories of Canada and received a […]
Bright Minds Biosciences Inc. to Webcast Live At VirtualInvestorConferences.com October 14th
NEW YORK , Oct. 7, 2021 /PRNewswire/ — BRIGHT MINDS BIOSCIENCES INC. (CSE: DRUG/OTCIQ: BMBIF), based in New York focused on new approaches to neuroscience, today announced that Ian McDonald , President & CEO and Josh Blacher , VP of Corporation Development, will present live at VirtualInvestorConferences.com on October 14 th . DATE: October 14 th , 2021TIME: 11:00 – 11:30 AM ETLINK: https://bit.ly/3kObcQO This will be a live, interactive online event where investors are […]
Silo Pharma achieves milestone – Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology
Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received approval from the DEA to advance the development of their Z-pod technology in combination with Ketamine. Eric Weisblum, CEO of Silo Pharma stated “The development of a […]
Small Pharma to Present at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021
KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021. Mr. Rands will discuss Small Pharma’s progress in the development of N,N-dimethyltryptamine (“DMT”) assisted therapy for the treatment of Major Depressive Disorder, through a live webcast on Wednesday, October 13, 2021, at 10:00 a.m. Eastern Time. If you would like to participate […]
Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison
San Diego, California–(Newsfile Corp. – October 7, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (” Tryp ” or the ” Company “), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today a collaboration with Paul Hutson, PharmD and Christopher Nicholas, PhD to support clinical pharmacology studies for the Company’s proprietary drug product, TRP-8803. […]
